 Aegis started coverage on shares of ImmuCell NASDAQ:ICCC in a research note released on Monday morning, The Fly reports. The brokerage issued a buy rating and a 14.00 target price on the biotechnology companys stock. Shares of NASDAQ:ICCC opened at 5.55 on Monday. ImmuCell has a 12-month low of 3.70 and a 12-month high of ... 